Author Archives: Bruno Quinney

Blood tests in laboratory
#Clinical trial #Crohn's disease #Ulcerative colitis (UC)

Infliximab could restore disease response after drug holiday 

Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows.  Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis… Read More

#News

#BioDot #Emulate #SLAS2026 #University of California San Francisco

SLAS2026 award winners announced 

Award winners at the SLAS2026 conference have been announced, with the event attracting a record number of attendees.  Steven Finkbeiner from Gladstone Institutes at the University of California San Francisco won the coveted Innovation Award for work on the ‘Development and Application of AI-powered Label-free Imaging for… Read More

#News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK

DDW Highlights: 17 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers made a key discovery into cancer survival. Elsewhere, a global research effort… Read More

#Podcasts

3d structure of the protein molecule
#AI #Drug design #Protein targets #Therapeutics

Galux raises $29m to advance AI-driven protein therapeutics 

Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform.  The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea… Read More

#Business & Investment #News

Respiratory system
#Cereno Scientific #Clinical trial #Hypertension #Idiopathic pulmonary fibrosis

Cereno Scientific to evaluate IPF drug as PH-ILD treatment 

An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).  CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a… Read More

#News

#Advanced Therapies #Cell therapy #Clinical trial #Rare diseases

BOOST appoints Schambye as CEO, advances cell therapy treatment  

Biopharmaceutical company BOOST Pharma has appointed Hans Schambye as Chief Executive Officer.   BOOST, a company developing novel, first–in–class off-the-shelf cell therapies for rare, debilitating paediatric skeletal diseases, announced Schambye has transitioned from his role on the Board of Directors with immediate effect into his new role as… Read More

#News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News

Human liver
#Clinical trial #Colorectal cancer #Liver disease

HepaRegeniX completes Phase Ib trial for liver regeneration drug 

Biotech company HepaRegeniX has completed a Phase Ib study evaluating a treatment for liver regeneration in patients undergoing minor liver resection.  Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection due to liver metastases originating from colorectal cancer. … Read More

#News

#Drug discovery #John Hopkins University #Syngene

Syngene and John Hopkins University to advance drug discovery  

Syngene International has announced a strategic collaboration with John Hopkins University to advance early-stage drug discovery programmes.  The collaboration will incorporate Syngene’s SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development.  … Read More

#Business & Investment #News

#AI #Automation #High throughput screening #SLAS2026

SLAS2026: AI, automation and high-throughput systems dominate 

From technology harnessing AI to launches of automation systems, DDW rounds up some of the biggest announcements from SLAS2026.      Carterra launches high-throughput SPR instrument    High-throughput technology provider Carterra launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform.  Read more…    SPT… Read More

#News

Researcher pipetting samples in microplate
#ABPI #Clinical trial #Non-animal model (NAM) #UK

UK must develop better pre-clinical models, ABPI warns 

The Association of the British Pharmaceutical Industry (ABPI) has urged scientists to develop better pre-clinical models to accelerate the development of new medicines. The ABPI, in collaboration with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), has published a landmark review examining the… Read More

#News #Regulatory

#Biomanufacturing #Fujifilm #NHS England #UK government

UK Chancellor hails FUJIFILM’s biomanufacturing expansion 

UK chancellor Rachel Reeves has hailed the expansion of FUJIFILM Biotechnologies facilities as “a vote of confidence in the UK”.  The Japanese company has expanded its facilities in the North East of England to support the biomanufacturing of innovative medicines and vaccines.  The company’s expanded… Read More

#News

#Advanced Therapies #Autoimmune disease #Cell therapy #Eli Lilly #Orna Therapeutics

Lilly to advance cell therapies after Orna acquisition 

Eli Lilly has acquired biotech company Orna Therapeutics to further develop its pipeline of cell therapies in autoimmune diseases.  Orna is advancing a new class of therapeutics utilising engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can… Read More

#Business & Investment #News

Flow cytometry
#Life sciences #Waters Corporation

Waters merges with BD Biosciences and Diagnostic Solutions 

Life science and diagnostics company Waters has announced its combination with BD Biosciences and Diagnostic Solutions to form a unified company.  The company aims to be a global leader in life sciences and diagnostics, having established a portfolio spanning liquid chromatography, mass spectrometry, materials characterisation, flow cytometry, and diagnostic… Read More

#News

#Blood cancer #Cancer Research UK #UK

Cancer Research UK invests £2.5m in blood cancer care 

Cancer Research UK has allocated £2.5 million ($3.4 million) to researchers at the University of York to help transform care for patients diagnosed with blood cancers.  The funding is for the world leading Haematological Malignancy Research Network (HMRN), one of the most comprehensive blood cancer research networks in the… Read More

#Cancer Research #News